Last reviewed · How we verify

Lymphoma — Treatment Landscape & Competitive Intelligence

Lymphoma (Haematology / Oncology) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Haematology / Oncology 3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pf-08032562 pf-08032562 Pfizer Inc. unknown unknown
Pf-07940369 pf-07940369 Pfizer Inc. Not available Not available
Pf-07923568 pf-07923568 Pfizer Unknown pharmacological class Unknown target

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 4 drugs in Lymphoma
  2. Pfizer · 1 drug in Lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Lymphoma:

Cite this brief

Drug Landscape (2026). Lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/lymphoma. Accessed 2026-05-13.

Related